Dedee Murrell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8603576/publications.pdf

Version: 2024-02-01

229 papers	9,298 citations	41344 49 h-index	45317 90 g-index
299 all docs	299 docs citations	299 times ranked	6885 citing authors

#	Article	IF	Citations
1	The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. Journal of the American Academy of Dermatology, 2008, 58, 931-950.	1.2	812
2	Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification. Journal of the American Academy of Dermatology, 2014, 70, 1103-1126.	1.2	747
3	Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. Journal of the American Academy of Dermatology, 2008, 58, 1043-1046.	1.2	464
4	Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. British Journal of Dermatology, 2020, 183, 614-627.	1.5	406
5	Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts. Journal of the American Academy of Dermatology, 2012, 66, 479-485.	1.2	294
6	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer, 2017, 17, 332.	2.6	291
7	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. Journal of the American Academy of Dermatology, 2020, 82, 575-585.e1.	1.2	224
8	A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8â€“20Âmm), with a 12â€•month followâ€up.. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 1302-1311.	2.4	208
9	Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus. Journal of Investigative Dermatology, 2009, 129, 2404-2410.	0.7	183
10	Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. Journal of Allergy and Clinical Immunology, 2020, 145, 173-182.	2.9	183
11	Towards global consensus on outcome measures for atopic eczema research: results of the <scp>HOME II</scp> meeting. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1111-1117.	5.7	169
12	Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2015, 72, 992-1002.	1.2	162
13	Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1900-1913.	2.4	159
14	Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. Clinical Reviews in Allergy and Immunology, 2018, 54, 26-51.	6.5	158
15	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Annals of the Rheumatic Diseases, 2017, 76, 543-546.	0.9	154
16	Should biologics for psoriasis be interrupted in the era of COVID-19?. Journal of the American Academy of Dermatology, 2020, 82, 1217-1218.	1.2	141
17	Definitions and outcome measures for mucous membrane pemphigoid: Recommendations ofÂanÂinternational panel of experts. Journal of the American Academy of Dermatology, 2015, 72, 168-174.	1.2	133
18	Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs non-Herlitz phenotypes. Human Genetics, 2002, 110, 41-51.	3.8	131

#	Article	IF	Citations
19	Inherited epidermolysis bullosa: New diagnostic criteria and classification. Clinics in Dermatology, 2012, 30, 70-77.	1.6	130
20	The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet Journal of Rare Diseases, 2020, 15, 1.	2.7	129
21	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. British Journal of Dermatology, 2018, 178, 768-775.	1.5	127
22	A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. Journal of the American Academy of Dermatology, 2011, 64, 903-908.	1.2	120
23	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2016, 175, 69-79.	1.5	115
24	Innate sensing of microbial products promotes wound-induced skin cancer. Nature Communications, 2015, 6, 5932.	12.8	113
25	Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. British Journal of Dermatology, 2009, 161, 1323-1330.	1.5	106
26	Fibroblast-Derived Dermal Matrix Drives Development of Aggressive Cutaneous Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis Bullosa. Cancer Research, 2012, 72, 3522-3534.	0.9	104
27	Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. British Journal of Dermatology, 2016, 174, 56-67.	1.5	102
28	Interventions for pemphigus vulgaris and pemphigus foliaceus. The Cochrane Library, 2009, , CD006263.	2.8	100
29	Epidermolysis Bullosa with Congenital Pyloric Atresia: Novel Mutations in the Î²4 Integrin Gene (ITGB4) and Genotype/Phenotype Correlations. Pediatric Research, 2001, 49, 618-626.	2.3	99
30	A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. Journal of the American Academy of Dermatology, 2013, 69, 898-908.e7.	1.2	95
31	APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Science Translational Medicine, 2018, 10, .	12.4	91
32	Autoantibodies to Type VII Collagen Recognize Epitopes in a Fibronectin-Like Region of the Noncollagenous (NC1) Domain. Journal of Investigative Dermatology, 1993, 100, 618-622.	0.7	87
33	European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology â€“ Part II. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1926-1948.	2.4	86
34	Epidemiology of Epidermolysis Bullosa in the Antipodes. Archives of Dermatology, 2010, 146, 635-40.	1.4	76
35	A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. British Journal of Dermatology, 2007, 157, 954-959.	1.5	72
36	European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology â€“ Part I. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1750-1764.	2.4	72

#	Article	IF	Citations
37	Development of a Quality-of-Life Instrument for Autoimmune Bullous Disease. JAMA Dermatology, 2013, 149, 1186.	4.1	70
38	Calculation of cutâ€•off values based on the Autoimmune Bullous Skin Disorder Intensity Score () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 for defining moderate, significant and extensive types of pemphigus. British Journal of Dermatology, 2016, 175, 142-149.	1.5	68
39	Suppression of TGF_{Î²}and Angiogenesis by Type VII Collagen in Cutaneous SCC. Journal of the National Cancer Institute, 2016, 108, djv293.	6.3	63
40	International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. British Journal of Dermatology, 2018, 179, 30-41.	1.5	62
41	A Comparative Study Between Transmission Electron Microscopy and Immunofluorescence Mapping in the Diagnosis of Epidermolysis Bullosa. American Journal of Dermatopathology, 2006, 28, 387-394.	0.6	57
42	Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). Journal of the American Academy of Dermatology, 2014, 70, 89-97.e13.	1.2	57
43	Review of autoimmune blistering diseases: the Pemphigoid diseases. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1685-1694.	2.4	56
44	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. Journal of Investigative Dermatology, 2019, 139, 31-37.	0.7	55
45	Diagnosis and Clinical Features of Pemphigus Vulgaris. Dermatologic Clinics, 2011, 29, 373-380.	1.7	54
46	The development and validation of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease. British Journal of Dermatology, 2013, 169, 1000-1006.	1.5	54
47	Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. British Journal of Dermatology, 2005, 152, 1219-1227.	1.5	53
48	Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in <scp>A</scp>ustralia. Australasian Journal of Dermatology, 2016, 57, 167-174.	0.7	53
49	Treatment considerations for patients with pemphigus during the COVID-19 pandemic. Journal of the American Academy of Dermatology, 2020, 82, e235-e236.	1.2	53
50	Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. The Cochrane Library, 2003, , CD004056.	2.8	44
51	Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*. British Journal of Dermatology, 2021, 185, 745-755.	1.5	42
52	How to Take Skin Biopsies for Epidermolysis Bullosa. Dermatologic Clinics, 2010, 28, 197-200.	1.7	38
53	Clinical heterogeneity in recessive epidermolysis bullosa due to mutations in the keratin 14 gene, KRT14. Clinical and Experimental Dermatology, 2008, 33, 689-697.	1.3	37
54	A comparison study of clinician-rated atopic dermatitis outcome measures for intermediate- to dark-skinned patients. British Journal of Dermatology, 2017, 176, 985-992.	1.5	37

#	Article	IF	Citations
55	The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAI and ABSIS) for Bullous Pemphigoid: Which One to Use?. Acta Dermato-Venereologica, 2017, 97, 24-31.	1.3	36
56	Evidence-Based Management of Bullous Pemphigoid. Dermatologic Clinics, 2011, 29, 613-620.	1.7	33
57	Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASIÂâ‰¥Â16) analysis of randomized phase 2B study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1562-1568.	2.4	33
58	Diagnosis and Clinical Features of Pemphigus Vulgaris. Immunology and Allergy Clinics of North America, 2012, 32, 233-243.	1.9	32
59	A pilot comparison study of four clinicianâ€rated atopic dermatitis severity scales. British Journal of Dermatology, 2015, 173, 488-497.	1.5	32
60	Age and etiology of childhood epidermolysis bullosa mortality. Journal of Dermatological Treatment, 2015, 26, 178-182.	2.2	31
61	The reliability and validity of outcome measures for atopic dermatitis in patients with pigmented skin: A grey area. International Journal of Women's Dermatology, 2015, 1, 150-154.	2.0	30
62	A quantitative approach to histopathological dissection of elastin-related disorders using multiphoton microscopy. British Journal of Dermatology, 2013, 169, 869-879.	1.5	29
63	Validation of theBIOCHIPtest for the diagnosis of bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 153-160.	2.4	29
64	The Epidermolysis Bullosa Disease Activity and Scarring Index (<scp>EBDASI</scp>): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 692-698.	2.4	28
65	Updated international expert recommendations for the management of autoimmune bullous diseases during the COVIDâ€19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e412-e414.	2.4	28
66	Outcome measures for autoimmune blistering diseases. Journal of Dermatology, 2015, 42, 31-36.	1.2	27
67	Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA. Quality of Life Research, 2015, 24, 2257-2260.	3.1	27
68	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. Frontiers in Medicine, 2018, 5, 306.	2.6	27
69	Quality of Life Measurements in Epidermolysis Bullosa: Tools for Clinical Research and Patient Care. Dermatologic Clinics, 2010, 28, 185-190.	1.7	25
70	Health-related Quality of Life in Epidermolysis Bullosa: Validation of the Dutch QOLEB Questionnaire and Assessment in the Dutch Population. Acta Dermato-Venereologica, 2014, 94, 442-447.	1.3	25
71	Cytoskeletal protein flightless I inhibits apoptosis, enhances tumor cell invasion and promotes cutaneous squamous cell carcinoma progression. Oncotarget, 2015, 6, 36426-36440.	1.8	25
72	Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey. Journal of the American Academy of Dermatology, 2021, 85, 1161-1167.	1.2	24

#	Article	IF	Citations
73	Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. Journal of the American Academy of Dermatology, 2021, 85, 1-14.	1.2	24
74	Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa. European Journal of Dermatology, 2015, 25, 30-32.	0.6	23
75	Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease â€“ specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires. Advances in Medical Sciences, 2017, 62, 92-96.	2.1	23
76	Prevalence of anemia in patients with epidermolysis bullosa registered in Australia. International Journal of Women's Dermatology, 2015, 1, 37-40.	2.0	22
77	Intraepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. Journal of the American Academy of Dermatology, 2021, 84, 1507-1519.	1.2	22
78	Infection and Infection Prevention in Patients TreatedÂwith Immunosuppressive Medications for Autoimmune Bullous Disorders. Dermatologic Clinics, 2011, 29, 591-598.	1.7	21
79	Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma. British Journal of Dermatology, 2013, 169, 208-210.	1.5	21
80	Translation, crossâ€cultural adaptation and validation of the Quality of Life Evaluation in Epidermolysis Bullosa instrument in Brazilian Portuguese. International Journal of Dermatology, 2016, 55, e94-9.	1.0	21
81	Alopecia in Epidermolysis Bullosa. Dermatologic Clinics, 2010, 28, 165-169.	1.7	19
82	Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis. Journal of Allergy and Clinical Immunology, 2021, 147, 1107-1109.e2.	2.9	18
83	Treatment of Pemphigus. Archives of Dermatology, 2008, 144, 100-1.	1.4	17
84	Hair Loss in Autoimmune Cutaneous Bullous Disorders. Dermatologic Clinics, 2011, 29, 503-509.	1.7	15
85	Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRNâ€473) in the treatment of canine pemphigus foliaceus. Veterinary Dermatology, 2020, 31, 291.	1.2	15
86	Epidermolysis Bullosa in Australia and New Zealand. Dermatologic Clinics, 2010, 28, 433-438.	1.7	14
87	Rituximab and shortâ€course prednisone as the new gold standard for newâ€onset pemphigus vulgaris and pemphigus foliaceus. British Journal of Dermatology, 2017, 177, 1143-1144.	1.5	14
88	What is novel in the clinical management of pemphigus. Expert Review of Clinical Pharmacology, 2019, 12, 973-980.	3.1	14
89	Financial burden of epidermolysis bullosa on patients in the United States. Pediatric Dermatology, 2020, 37, 1198-1201.	0.9	14
90	Open trial of Brutonâ€™s tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus. Veterinary Dermatology, 2020, 31, 410.	1.2	14

#	Article	IF	Citations
91	A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases. Orphanet Journal of Rare Diseases, 2018, 13, 83.	2.7	13
92	Update on COVID â€19 effects in dermatology specialty. Dermatologic Therapy, 2020, 33, e13523.	1.7	13
93	No Evidence That Human Papillomavirus Is Responsible for the Aggressive Nature of Recessive Dystrophic Epidermolysis Bullosaâ€“Associated Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2010, 130, 2853-2855.	0.7	12
94	Advances in understanding and managing bullous pemphigoid. F1000Research, 2015, 4, 1313.	1.6	12
95	Clinical application of a molecular assay for the detection of dermatophytosis and a novel non-invasive sampling technique. Pathology, 2016, 48, 720-726.	0.6	12
96	Prevalence and pathogenesis of osteopenia and osteoporosis in epidermolysis bullosa: An evidenceâ€based review. Experimental Dermatology, 2019, 28, 1122-1130.	2.9	12
97	A dermatologist's perspective of the <scp>COVID</scp> â€19 outbreak. Dermatologic Therapy, 2020, 33, e13538.	1.7	12
98	Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: Validation of the translated Persian version in pemphigus vulgaris. International Journal of Women's Dermatology, 2020, 6, 306-310.	2.0	12
99	Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy. Journal of the American Academy of Dermatology, 2021, 85, 18-27.	1.2	12
100	Dupilumab-associated ocular manifestations: A review of clinical presentations and management. Survey of Ophthalmology, 2022, 67, 1419-1442.	4.0	12
101	Mucous membrane pemphigoid: are laminin 5 antibodies a risk factor for laryngeal involvement?. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 169-170.	2.4	11
102	Scoring Systems for Blistering Diseases in Practice. JAMA Dermatology, 2014, 150, 245.	4.1	11
103	Management of pemphigus. F1000prime Reports, 2014, 6, 32.	5.9	11
104	Marked intrafamilial phenotypic heterogeneity in dystrophic epidermolysis bullosa caused by inheritance of a mild dominant glycine substitution and a novel deep intronic recessiveCOL7A1mutation. British Journal of Dermatology, 2016, 174, 1122-1125.	1.5	11
105	A review of caseâ€“control studies on the risk factors for the development of autoimmune blistering diseases. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 595-603.	2.4	11
106	Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy. Journal of the American Academy of Dermatology, 2021, 84, 1523-1537.	1.2	11
107	The impact of gender in mentorâ€“mentee success: Results from the Women's Dermatologic Society Mentorship Survey. International Journal of Women's Dermatology, 2021, 7, 398-402.	2.0	11
108	Advancement of women in dermatology. International Journal of Dermatology, 2011, 50, 593-600.	1.0	10

#	Article	IF	Citations
109	Outcomes of 11 pregnancies in three patients with recessive forms of epidermolysis bullosa. British Journal of Dermatology, 2011, 165, 700-701.	1.5	10
110	Reliability and validity of the Chinese version of the autoimmune bullous disease quality of life (ABQOL) questionnaire. Health and Quality of Life Outcomes, 2017, 15, 31.	2.4	10
111	Quality of Life in Greek Patients with Autoimmune Bullous Diseases Assessed with ABQOL and TABQOL Indexes. Acta Dermato-Venereologica, 2017, 97, 1145-1147.	1.3	10
112	The effect of autoimmune blistering diseases on work productivity. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1959-1966.	2.4	10
113	Overâ€expression of stromal periostin correlates with poor prognosis of cutaneous squamous cell carcinomas. Experimental Dermatology, 2021, 30, 698-704.	2.9	10
114	Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseasesâ€™ patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires. Anais Brasileiros De Dermatologia, 2019, 94, 399-404.	1.1	10
115	Naevus of Ota presenting in two generations: a mother and daughter. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 102-104.	2.4	9
116	Digenic inheritance in epidermolysis bullosa simplex involving two novel mutations in KRT5 and KRT14. British Journal of Dermatology, 2017, 177, 262-264.	1.5	9
117	Interâ€rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2327-2333.	2.4	9
118	Autoimmune bullous diseases during pregnancy: Solving common and uncommon issues. International Journal of Women's Dermatology, 2019, 5, 166-170.	2.0	9
119	<scp>COVID</scp> â€19 and immunosuppressive therapy in dermatology. Dermatologic Therapy, 2020, 33, e14140.	1.7	9
120	Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study. Orphanet Journal of Rare Diseases, 2020, 15, 190.	2.7	9
121	Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus. Frontiers in Medicine, 2021, 8, 708071.	2.6	9
122	Psoriasis and osteoporosis: a literature review. Clinical and Experimental Dermatology, 2022, 47, 1438-1445.	1.3	9
123	Disease-specific health related quality of life patient reported outcome measures in Genodermatoses: a systematic review and critical evaluation. Orphanet Journal of Rare Diseases, 2017, 12, 189.	2.7	8
124	Where do we stand as dermatologists in combat with <scp>COVID</scp> â€19. Dermatologic Therapy, 2020, 33, e13638.	1.7	8
125	Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemicâ€”Consensus: Recommendations by an international panel of experts. Journal of the American Academy of Dermatology, 2020, 83, 1222-1224.	1.2	7
126	Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study). Orphanet Journal of Rare Diseases, 2020, 15, 158.	2.7	7

#	Article	IF	Citations
127	Treatment concerns for bullous pemphigoid in the <scp>COVID</scp> â€19 pandemic era. Dermatologic Therapy, 2020, 33, e13956.	1.7	7
128	The Potential Protective Effect of Estrogen: Why is COVID-19 mortality lower in females than males. International Journal of Women's Dermatology, 2020, 6, 152-153.	2.0	7
129	A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB). JAAD International, 2021, 2, 134-152.	2.2	7
130	Assessing the quality of life in the families of patients with epidermolysis bullosa: The mothers as main caregivers. International Journal of Women's Dermatology, 2021, 7, 721-726.	2.0	7
131	Treatment of pemphigus vulgaris and pemphigus foliaceus. Expert Review of Dermatology, 2009, 4, 469-481.	0.3	6
132	Pigmented Hair-Thickening Fibers: A Camouflage Technique for Alopecia in Patients with Epidermolysis Bullosa. Skin Appendage Disorders, 2015, 1, 153-155.	1.0	6
133	Chlorophyllâ€induced pseudoporphyria with ongoing photosensitivity after cessation â€“ a case series of four patients. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1239-1242.	2.4	6
134	An Atypical Localized Form of Hidradenitis Suppurativa of the Jawline and Neck Mimicking Severe Cystic Acne on Presentation. Skin Appendage Disorders, 2017, 3, 215-218.	1.0	6
135	Drugâ€related adverse effects of vismodegib and sonidegib for locally advanced or metastatic basal cell carcinoma. Australasian Journal of Dermatology, 2020, 61, 176-177.	0.7	6
136	Outcomes and Predictors for Reâ€stenosis of Esophageal Stricture in Epidermolysis Bullosa. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 310-314.	1.8	6
137	Use of face masks in dermatology department during the <scp>COVID</scp> â€19 outbreak. Dermatologic Therapy, 2020, 33, e13521.	1.7	6
138	Sensitivity to change and correlation between the autoimmune bullous disease qualityâ€ofâ€life questionnaires <scp>ABQOL</scp> and <scp>TABQOL</scp> , and objective severity scores. British Journal of Dermatology, 2020, 183, 944-945.	1.5	6
139	Restructuring an academic dermatology practice during the COVID â€19 pandemic. Dermatologic Therapy, 2020, 33, e13684.	1.7	6
140	Patientâ€reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global crossâ€sectional survey. Pediatric Dermatology, 2021, 38, 1198-1201.	0.9	6
141	Conducting dermatology clinical trials during the COVID-19 pandemic. Clinics in Dermatology, 2021, 39, 104-106.	1.6	6
142	Management of epidermolysis bullosa. Expert Opinion on Orphan Drugs, 2013, 1, 279-293.	0.8	5
143	Successful management of bullous pemphigoid with dimethyl fumarate therapy: A case report. International Journal of Women's Dermatology, 2019, 5, 179-180.	2.0	5
144	Virtual conferences of dermatology during the COVID â€19 pandemic. Dermatologic Therapy, 2020, 33, e13774.	1.7	5

#	Article	IF	Citations
145	Multiple milia formation in blistering diseases. International Journal of Women's Dermatology, 2020, 6, 199-202.	2.0	5
146	Successful dapsone therapy in inherited epidermolysis bullosa. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e333-e334.	2.4	5
147	GDF6 Knockdown in a Family with Multiple Synostosis Syndrome and Speech Impairment. Genes, 2021, 12, 1354.	2.4	5
148	Chinese version of the treatment of autoimmune bullous disease quality of life questionnaire: Reliability and validity. Indian Journal of Dermatology, Venereology and Leprology, 2018, 84, 431.	0.6	5
149	Biological medication in atopic dermatitis. Expert Opinion on Biological Therapy, 2022, , 1-7.	3.1	5
150	A comparison in real clinical practice of methyl aminolevulinate photodynamic therapy and surgery for small superficial basal cell carcinoma: 3-year recurrence rates and cosmetic outcomes. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 117-118.	2.4	4
151	Multiple cutaneous reticulohistiocytomas successfully treated with topical psoralen plus ultraviolet A therapy combined with intralesional injections of triamcinolone acetonide. JAAD Case Reports, 2015, 1, 157-159.	0.8	4
152	Retrospective evidence on outcomes and experiences of pregnancy and childbirth in epidermolysis bullosa in Australia and New Zealand. International Journal of Women's Dermatology, 2015, 1, 26-30.	2.0	4
153	Recessive dystrophic epidermolysis bullosa (RDEB) complicated by secondary hepatic amyloidosis. JAAD Case Reports, 2015, 1, 337-339.	0.8	4
154	What is the true mortality from pemphigus?. British Journal of Dermatology, 2016, 174, 1185-1186.	1.5	4
155	Highly Resistant Acrodermatitis Continua of Hallopeau and Pustular Psoriasis. Skin Appendage Disorders, 2017, 3, 179-181.	1.0	4
156	Pathogenesis and clinical features of alopecia in epidermolysis bullosa: A systematic review. Pediatric Dermatology, 2019, 36, 430-436.	0.9	4
157	Authors' reply to the comment â€œTreatment considerations for patients with pemphigus during the COVID-19 pandemicâ€• Journal of the American Academy of Dermatology, 2021, 84, e61-e62.	1.2	4
158	Impact of COVIDâ€19 on inpatient dermatology consults in an Australian tertiary hospital. Australasian Journal of Dermatology, 2021, 62, 427-428.	0.7	4
159	Multiple sclerosis is the neurological disorder most highly associated with bullous pemphigoid. British Journal of Dermatology, 2017, 176, 1428-1429.	1.5	4
160	Recommendations on pregnancy, childbirth and aftercare in epidermolysis bullosa: a consensusâ€based guideline*. British Journal of Dermatology, 2022, 186, 620-632.	1.5	4
161	Preface. Dermatologic Clinics, 2010, 28, xix.	1.7	3
162	The International Pemphigus and Pemphigoid Foundation. Dermatologic Clinics, 2011, 29, 655-657.	1.7	3

#	Article	IF	Citations
163	Is the Oral Disease Severity Score going to be useful for dermatologists when assessing pemphigus?. British Journal of Dermatology, 2018, 179, 816-817.	1.5	3
164	A chlorhexidine conundrum after an epidural delivery: The difficulty of differentiating between chlorhexidine burns and hypersensitivity reactions. International Journal of Women's Dermatology, 2019, 5, 269-270.	2.0	3
165	Role of music therapy in reducing the burden of dermatological diseases during <scp>COVID</scp> â€19. Dermatologic Therapy, 2020, 33, e14086.	1.7	3
166	Reply to: â€œCOVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of cautionâ€• Journal of the American Academy of Dermatology, 2020, 82, e215.	1.2	3
167	An analysis of the prevalence of osteoporosis and osteopenia in patients with epidermolysis bullosa: A crossâ€sectional study. Experimental Dermatology, 2021, 30, 1675-1685.	2.9	3
168	Shedding light on the impact of hidradenitis suppurativa on women and their families: A focus of the International Journal of Women's Dermatology. International Journal of Women's Dermatology, 2021, 7, 661-663.	2.0	3
169	Topical Corticosteroids in Blistering Diseases. , 2018, , 91-100.		3
170	Allergic contact dermatitis to miconazole for nipple candidiasis. Contact Dermatitis, 2022, 87, 201-202.	1.4	3
171	Phase 2 <scp>BELIEVE</scp> study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	3
172	A complicated blistering disease case demonstrating the usefulness of immunoblotting and ELISA for the diagnosis of immunobullous diseases. Australasian Journal of Dermatology, 2006, 47, A57-A57.	0.7	2
173	Autoimmune Diseases of the Skin. Immunology and Allergy Clinics of North America, 2012, 32, xiii-xiv.	1.9	2
174	Autoimmune Blistering Diseases and Corticosteroid Use: A Review of the Evidence. , 2015, , 459-468.		2
175	Genetic screening for human leukocyte antigen alleles prior to carbamazepine treatment. Journal of Clinical Neuroscience, 2015, 22, 1992-1993.	1.5	2
176	Epidermolysis Bullosa Patients' Perception of Surgical Wound and Scar Healing. Dermatologic Surgery, 2019, 45, 280-289.	0.8	2
177	Dermatology and specialty rotations:<scp>COVID</scp>â€19 may reemphasize the importance of internal medicine. Dermatologic Therapy, 2020, 33, e13996.	1.7	2
178	Splicing of the cake can affect the severity of epidermolysis bullosa. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1879-1880.	2.4	2
179	Reply to: â€œBiologics for psoriasis during COVID-19 outbreakâ€• Journal of the American Academy of Dermatology, 2020, 82, e219.	1.2	2
180	Heralding change within dermatology: Response of the International Journal of Womenâ€™s Dermatology (IJWD) to the twin pandemic of racism. International Journal of Women's Dermatology, 2021, 7, 125-126.	2.0	2

#	Article	IF	Citations
181	Are biosimilars for pemphigus safe?. Clinical and Experimental Dermatology, 2021, 46, 942-943.	1.3	2
182	Managing epidermolysis bullosa during the coronavirus pandemic: Experience and ideals. Clinics in Dermatology, 2021, 39, 369-373.	1.6	2
183	Beyond the skin: disease parameters in pemphigus. Italian Journal of Dermatology and Venereology, 2021, 156, 147-150.	0.2	2
184	Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study. Indian Journal of Dermatology, Venereology and Leprology, 2021, 88, 177-183.	0.6	2
185	Comparison of effectiveness of topical tacrolimus 0.1% vs topical halobetasol propionate 0.05% as an addâ€on to oral hydroxychloroquine in discoid lupus erythematosus. Dermatologic Therapy, 2021, 34, e14675.	1.7	2
186	Clinical features of chronic bullous dermatosis of childhood. Clinical and Experimental Dermatology, 2022, 47, 873-881.	1.3	2
187	How Do Experts Treat Patients with BullousÂPemphigoid around the World? AnÂInternational Survey. JID Innovations, 2022, 2, 100129.	2.4	2
188	Mental health, insomnia and suicidal ideation during treatment with apremilast. Australasian Journal of Dermatology, 2022, 63, 403-404.	0.7	2
189	Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men. International Journal of Women's Dermatology, 2022, 8, e004.	2.0	2
190	A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex. Orphanet Journal of Rare Diseases, 2022, 17, .	2.7	2
191	Preface. Dermatologic Clinics, 2010, 28, xv-xvi.	1.7	1
192	Bullous pemphigoid: therapeutic algorithm and practical management. Expert Opinion on Orphan Drugs, 2013, 1, 405-412.	0.8	1
193	Inherited epidermolysis bullosa. Journal of the Egyptian Women's Dermatologic Society, 2014, 11, 1-13.	0.1	1
194	Burden of disease scoring in epidermolysis bullosa. British Journal of Dermatology, 2015, 173, 1357-1358.	1.5	1
195	Cover image: Unpeeling the layers of harlequin ichthyosis. British Journal of Dermatology, 2016, 174, 1160-1161.	1.5	1
196	Why have hospitalization rates for bullous pemphigoid soared?. British Journal of Dermatology, 2017, 176, 5-6.	1.5	1
197	Editorial: Skin Blistering Diseases. Frontiers in Medicine, 2019, 6, 60.	2.6	1
198	Diagnostic Criteria and Phenotypes of Pemphigoid and the Association With Gliptins. JAMA Dermatology, 2019, 155, 147.	4.1	1

#	Article	IF	Citations
199	Novel diagnostic method to differentiate antilaminin‚Ä332 pemphigoid from other forms of pemphigoid. British Journal of Dermatology, 2020, 182, 270-271.	1.5	1
200	A prickly souvenir from a hedgehog cafÃ©: tinea manuum secondary to Trichophyton erinacei via international spread. Clinical and Experimental Dermatology, 2020, 45, 459-461.	1.3	1
201	International collaboration. Journal of Dermatological Treatment, 2020, 31, 757-757.	2.2	1
202	Osteoporosis and bone health in autoimmune blistering skin diseaseâ€"an evidenced based review. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2745-2756.	2.4	1
203	Ectropion surgery might not be a longâ€term solution for harlequin ichthyosis. Dermatologic Therapy, 2021, 34, e14646.	1.7	1
204	Embracing diversity in dermatology: Creation of a culture of inclusion in dermatologic publishing. International Journal of Women's Dermatology, 2021, 7, 371-377.	2.0	1
205	Atopic Dermatitis Outcome Measures. , 2019, , 1-28.		1
206	Training and retaining physician scientists in dermatology: Australia. JID Innovations, 2021, 2, 100074.	2.4	1
207	Assessment of published literature regarding skin of color in Pediatric Dermatology. Pediatric Dermatology, 2021, 38, 1604-1605.	0.9	1
208	Preface. Dermatologic Clinics, 2011, 29, xv-xvi.	1.7	0
209	Screening for infections prior to initiating immunosuppressive treatment for patients with autoimmune blistering diseases. British Journal of Dermatology, 2014, 171, 1285-1286.	1.5	0
210	Cover Image: The many faces of sarcoidosis. British Journal of Dermatology, 2016, 175, 1111-1112.	1.5	0
211	Increasing prevalence but not incidence of psoriasis in the U.K.. British Journal of Dermatology, 2017, 176, 568-569.	1.5	0
212	Patients left behind: Rare dermatologic conditions miss the orphan drug development boom. Journal of the American Academy of Dermatology, 2019, 81, 1025-1026.	1.2	0
213	Atopic Dermatitis Outcome Measures. , 2019, , 1-28.		0
214	Pemphigus vulgaris accompanied with amyotrophic lateral sclerosis: a rare coincidence or pathogenic relationship?. European Journal of Dermatology, 2019, 29, 435-436.	0.6	0
215	Mycobacterium chelonae infection mimicking Demodex folliculitis. Clinical and Experimental Dermatology, 2020, 45, 469-470.	1.3	0
216	Predatory journals: The silent intruder. Dermatologic Therapy, 2020, 33, e13214.	1.7	0

#	Article	IF	Citations
217	The response of the Womenâ€™s Dermatologic Society and the International Journal of Womenâ€™s Dermatology to the COVID-19 pandemic. International Journal of Women's Dermatology, 2020, 6, 129-130.	2.0	0
218	Cardiac Involvement in Epidermolysis Bullosa. , 2021, , 33-48.		0
219	The Importance of Cardiac Assessment in the Era of Biologic Therapies for Psoriasis. , 2021, , 419-430.		0
220	What instruments should we add to our toolbox for measuring the severity and control of eczema?. British Journal of Dermatology, 2021, 185, 13-14.	1.5	0
221	Individual patientsâ€™ risk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximab. Journal of the American Academy of Dermatology, 2021, 85, e47-e48.	1.2	0
222	Stateâ€ofâ€theâ€art review of human autoimmune blistering diseases (AIBD). Veterinary Dermatology, 2021, 32, 524-e145.	1.2	0
223	Evaluating diversity in Clinics in Dermatology. Clinics in Dermatology, 2021, 39, 1064-1066.	1.6	0
224	Diagnosis and Prevention of Bullous Diseases. , 2011, , 115-135.		0
225	Diagnosis and Prevention of Bullous Diseases. , 2011, , 53-73.		0
226	Celebrating Outstanding Science at the European Academy of Dermatology and Venereologyâ€™s 30th Anniversary Congress. EMJ Dermatology, 0, , 24-28.	0.0	0
227	Dermatoethics: Nepotism in dermatology residencies. Journal of the American Academy of Dermatology, 2023, 89, 193-194.	1.2	0
228	Sebaceous cell carcinoma presenting as ocular Marjolin ulcer following immunosuppression for a chemical burn. Canadian Journal of Ophthalmology, 2022, , .	0.7	0
229	Proposed management algorithm for dupilumabâ€associated ocular side effects: a collaborative effort between dermatologists and ophthalmologists. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	0